Cardiovascular disease is highly prevalent in HIV-positive patients and can be explored with coronary artery calcium score as a biomarker of preclinical coronary disease. Antiretroviral drugs and concomitant treatment including second generation anti-psychotics may contribute to metabolic derangement with potential impact on traditional cardiovascular risk factors associated with the metabolic syndrome phenotype. The objective of the study was to assess the impact of second generation anti-psychotics on subclinical cardiovascular disease in HIV positive patients.
HIV patients undergoing second generation antipsychotics show high cardiovascular disease burden / Ferrara, M; Malagoli, Andrea; Garlassi, Sara; Stentarelli, Chiara; Zona, Stefano; Carli, Federica; Menozzi, Marianna; Santoro, Antonella; Raggi, P; Starace, F; Mussini, Cristina; Guaraldi, Giovanni. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - STAMPA. - 20:(2015), pp. 53-54. (Intervento presentato al convegno 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV tenutosi a Barcellona, Spagna nel 20-22 ottobre 2015).
HIV patients undergoing second generation antipsychotics show high cardiovascular disease burden
MALAGOLI, Andrea;GARLASSI, SARA;STENTARELLI, Chiara;ZONA, Stefano;CARLI, FEDERICA;Menozzi, Marianna;SANTORO, ANTONELLA;MUSSINI, Cristina;GUARALDI, Giovanni
2015
Abstract
Cardiovascular disease is highly prevalent in HIV-positive patients and can be explored with coronary artery calcium score as a biomarker of preclinical coronary disease. Antiretroviral drugs and concomitant treatment including second generation anti-psychotics may contribute to metabolic derangement with potential impact on traditional cardiovascular risk factors associated with the metabolic syndrome phenotype. The objective of the study was to assess the impact of second generation anti-psychotics on subclinical cardiovascular disease in HIV positive patients.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
